As of May, 24 Bavarian Nordic A/S (BVNRY) Analysts See $-0.25 EPS

May 16, 2018 - By Matthew Richard

Bavarian Nordic A/S (OTCMKTS:BVNRY) Corporate Logo

Bavarian Nordic A/S (OTCMKTS:BVNRY)’s earnings report is anticipated on May, 24 before the open., Zacks reports. Analysts forecast 2,400.00 % diference or $-0.25 from the $-0.01 EPS from 2017. Last quarter $-0.31 earnings per share was reported. Analysts forecasts -19.35 % EPS growth this quarter. $9.91 was the last price.It’s since May 16, 2017 and is 0.00% down. BVNRY underperformed by 11.55% the S&P 500.

Bavarian Nordic A/S, a biotechnology company, develops, makes, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer.The firm is valued at $960.01 million. The firm markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names.The P/E ratio is 31.66. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: